ULURU Inc. Announces First Shipment Of Altrazeal® To The Czech Republic, Slovakia And South African Marketing Partners

Oct 02, 2013, 08:00 ET from ULURU Inc.

ADDISON, Texas, Oct. 2, 2013 /PRNewswire/ -- ULURU Inc. (OTCQB: ULUR), today announced it has completed the first shipments of Altrazeal® to the Czech Republic/Slovakia and South African marketing partners.

Commenting on the initial shipments, Helmut Kerschbaumer, Managing Director of Altrazeal GmbH, stated, "Extensive work has been conducted preparing for the launch of Altrazeal® in these markets, including participation at wound care conferences, conducting clinical case studies and training wound care professionals and our marketing partners. We are confident that our marketing partners are well positioned to establish Altrazeal® as a major competitor in the advanced wound care market. We are looking forward to launching Altrazeal® in additional markets in the fourth quarter 2013."

Altrazeal® is a scientifically engineered advanced wound dressing designed to incorporate the desired features and benefits of the ideal wound dressing. Altrazeal® competes in the advanced wound dressing market which, worldwide, is estimated to be $6.5 billion growing annually at 13%. Altrazeal® has demonstrated potential clinical and economic advantages in a number of chronic and acute wounds including diabetic foot ulcers, venous leg ulcers and geriatric wounds.

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system.  For further information about ULURU Inc., please visit our website at www.ULURUinc.com.  For further information about Altrazeal®, please visit www.Altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended.  These statements are subject to numerous risks and uncertainties, including but not limited to the launch of Altrazeal® in the territory, the commercial potential of Altrazeal®, the establishment of Altrazeal® as a major competitor and the demonstration of cost savings and clinical benefits, and the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, and other reports filed by us with the Securities and Exchange Commission.

Contact: Company
Kerry P. Gray 
President & CEO 
Terry K. Wallberg 
Vice President & CFO
(214) 905-5145